Research Reports

$14.9B in revenue last year — tripled YoY — yet the stock trades at 8x earnings because of an auditor change and a DOJ inquiry. We dug into the filings to separate the governance noise from the business reality.

A $25M market cap company with a SaaS product growing 45% YoY at 72% gross margins — and zero analyst coverage. Their DataV IoT platform is quietly replacing legacy device management across industrial customers.

Uranium spot hit $90/lb and Ur-Energy produces at $28/lb. That's a 61% gross margin on a commodity with a structural supply deficit. Every $10/lb move in uranium adds $6M to their EBITDA — and most analysts expect $100+ by 2027.

For every barrel of Permian oil, 4-6 barrels of water come up — and disposing of it is legally required. Aris runs 1,500 miles of pipeline handling 1.2M barrels/day on 85% take-or-pay contracts. It's a regulated utility disguised as an oilfield services stock, trading at 8x EBITDA.

Down 85% from its 2021 peak, BioAtla trades at $35M enterprise value — less than zero after you back out cash. Two new clinical programs enter readouts in 2026. If either works, you're looking at a 3-5x. If not, you still have $2.20/share in cash.

Enterprise value: $7M. Target market: $5B+. Liminal's first-in-class OXER1 inhibitor for pulmonary fibrosis has orphan drug status and 2.7 years of cash runway — no dilution needed to reach Phase 2 data. The risk/reward math at this valuation is hard to ignore.

A $127M micro-cap with $65K in annual revenue just spiked 41% because its quantum-engineered silicon film may solve the biggest manufacturing challenge in 2nm Gate-All-Around chips. The science is real. The financials are terrifying. Here's why that might not matter.

A $168M market cap company holding 1,000 BTC (~$89M) and building the first retail tokenized deposit platform with Uphold and Vast Bank. CEO Greg Kidd was first money into Twitter, Square, Coinbase, Ripple, and Solana. At $0.42, you're getting the deposit business for free.

Rackspace surged 229% after announcing a Palantir partnership to deploy managed AI for regulated enterprises. At 0.12x trailing P/S with $2.5B in debt, this is either the most credible turnaround catalyst since the re-IPO or a dead cat bounce on a hail mary press release.

Moolec surged 90% on validated 45% GLA concentration from engineered safflower at commercial scale. The science is real — 1,100 acres, standard crushing infrastructure, genuinely differentiated molecular farming. But a $7M market cap, going concern language, and a June 2026 Nasdaq deadline make this a watch-and-wait.

KNRX surged 245% on an 'agentic AI' API launch, but underneath the buzzword sits $0.2M cash, $8.2M debt, shrinking revenue, and 2-3 weeks of runway. We break down why the narrative doesn't match the balance sheet.

A $7-10M market cap bitcoin miner doing $7.4M in LTM revenue with sub-$0.04/kWh power costs, two Tennessee facilities, and operating profit up 207% YoY. Trades below book value. The catch: $94K cash and a $3M loan at 12%.

Sensient Technologies is a specialty ingredients company that has quietly compounded returns for decades. Trading at reasonable valuations with strong pricing power and secular tailwinds in natural colors and flavors.

Prelude Therapeutics is a clinical-stage precision oncology company at a strategic inflection point following FDA IND clearance for PRT12396 (JAK2V617F inhibitor) and Incyte partnership. High-risk/high-reward microcap with validated targets.